Organic Novavax announced Tuesday data from a preclinical study of a vaccine combination that works against both seasonal influenza and Covid-19. The company announced that the combination vaccine consisting of the NanoFlu / NVX and CoV2373 vaccine showed positive immune reactions to both influenza and SARS-CoV-2.
The combination vaccine elicited “convincing reactions” to influenza A and B and protected it from SARS-CoV-2. Clinical studies on the combination vaccine are expected to begin by the end of the year.
However it is The study is currently only available as a template And publish it on the appropriate server. Before it appears in a niche magazine, it must first be vetted by independent experts.
Existing preclinical studies with hamsters and rodents examined how the combined active ingredient affected viral infection. The influenza vaccine is a quadrivalent (effective against four strains of the virus) vaccine for influenza nanoparticles and a recombinant SARS-CoV-2 vaccine that targets the elevated proteins of the virus. After two weeks, the animals formed clearly detectable antibodies.
Novavax emphasizes the importance of these double effective vaccines. “Combined vaccines for seasonal influenza and COVID-19 are expected to be critical in combating emerging variants of COVID-19,” said Russell “Rep” Wilson, Executive Vice President and General Manager of NanoFlu at Novavax. “